TENX
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. insider trading
Tenax Therapeutics, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent TENX insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
TENX insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded TENX on the open market: 15 purchases worth $204.5K and 0 sales. In the last four quarters alone: 15 purchases ($204.5K) and 0 sales, by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | +$204.5K15 buys | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest purchase
- +$36.2K of TENX by McGauley Thomas (Interim CFO) on Nov 17, 2025.
Open-market transactions through Jun 30, 2026most recent first
Rich Stuart
Chief Medical Officer · Director
+$25.6K
Dec 09, 2025
2,500 sh · $10.22
Rich Stuart
Chief Medical Officer · Director
+$25.3K
Dec 08, 2025
2,500 sh · $10.10
Rich Stuart
Chief Medical Officer · Director
+$23K
Dec 04, 2025
2,500 sh · $9.20
Rich Stuart
Chief Medical Officer · Director
+$13.6K
Dec 03, 2025
1,500 sh · $9.08
Rich Stuart
Chief Medical Officer · Director
+$9K
Dec 02, 2025
1,000 sh · $9.01
Giordano Christopher Thomas
CEO · Director
+$4.1K
Nov 20, 2025
538 sh · $7.59
Giordano Christopher Thomas
CEO · Director
+$3.4K
Nov 19, 2025
455 sh · $7.51
Almenoff June Sherie
Director
+$14.3K
Nov 18, 2025
1,900 sh · $7.52
Almenoff June Sherie
Director
+$14.3K
Nov 18, 2025
1,900 sh · $7.52
Giordano Christopher Thomas
CEO · Director
+$12.5K
Nov 18, 2025
1,612 sh · $7.75
McGauley Thomas
Interim CFO
+$36.2K
Nov 17, 2025
5,000 sh · $7.23
McGauley Thomas
Interim CFO
+$14.7K
Nov 17, 2025
2,000 sh · $7.34
McGauley Thomas
Interim CFO
+$7.4K
Nov 17, 2025
1,000 sh · $7.35
Almenoff June Sherie
Director
+$665
Nov 17, 2025
93 sh · $7.15
Almenoff June Sherie
Director
+$665
Nov 17, 2025
93 sh · $7.15
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 09, 2025 | Rich StuartChief Medical Officer · Director | 2,500 | $10.22 | +$25.6K |
| Dec 08, 2025 | Rich StuartChief Medical Officer · Director | 2,500 | $10.10 | +$25.3K |
| Dec 04, 2025 | Rich StuartChief Medical Officer · Director | 2,500 | $9.20 | +$23K |
| Dec 03, 2025 | Rich StuartChief Medical Officer · Director | 1,500 | $9.08 | +$13.6K |
| Dec 02, 2025 | Rich StuartChief Medical Officer · Director | 1,000 | $9.01 | +$9K |
| Nov 20, 2025 | Giordano Christopher ThomasCEO · Director | 538 | $7.59 | +$4.1K |
| Nov 19, 2025 | Giordano Christopher ThomasCEO · Director | 455 | $7.51 | +$3.4K |
| Nov 18, 2025 | Almenoff June SherieDirector | 1,900 | $7.52 | +$14.3K |
| Nov 18, 2025 | Almenoff June SherieDirector | 1,900 | $7.52 | +$14.3K |
| Nov 18, 2025 | Giordano Christopher ThomasCEO · Director | 1,612 | $7.75 | +$12.5K |
| Nov 17, 2025 | McGauley ThomasInterim CFO | 5,000 | $7.23 | +$36.2K |
| Nov 17, 2025 | McGauley ThomasInterim CFO | 2,000 | $7.34 | +$14.7K |
| Nov 17, 2025 | McGauley ThomasInterim CFO | 1,000 | $7.35 | +$7.4K |
| Nov 17, 2025 | Almenoff June SherieDirector | 93 | $7.15 | +$665 |
| Nov 17, 2025 | Almenoff June SherieDirector | 93 | $7.15 | +$665 |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check TENX — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Tenax Therapeutics, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much TENX stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 Tenax Therapeutics, Inc. insiders made 15 open-market purchases worth $204.5K and no sales. In the four quarters to Jun 30, 2026: 15 purchases ($204.5K) and no sales. The largest purchase was McGauley Thomas buying $36.2K on Nov 17, 2025.
- Where does TENX insider trading data come from?
- From the Form 4 filings Tenax Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.